← Analyst Upside
AU · rank #15 · 2026-10-20
EOLS
NASDAQ · $486M (USD)
SignalBuy1.5strength 1.5 / 10
verdict · PROCEED
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.261 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.02 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 4 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.193 |
| Analyst upside Consensus target $15.00 | +103.8% |
| Momentum acceleration 3-month minus 12-month momentum. | +22.45% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.50 |
| Gross margin TTM | +66.4% |
| 52w high | $9.31 |
| Market cap (USD) | $486M |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Evolus Inc is a commercial medical aesthetics company selling Jeuveau and Nuceiva neurotoxins alongside Evolysse and Estyme hyaluronic acid dermal fillers.
Rationale
The analyst upside signal is supported by 100% positive 30-day revision agreement, a 52.6% earnings surprise, and a management guidance raise to $330–337 million in 2026 revenue.
Material risks
- 1FDA regulatory action following the October 2026 untitled letter regarding Jeuveau promotional claims could require corrective marketing and impair provider adoption.
- 2Balance sheet risk from $156.7 million in long-term debt relative to $45.2 million in cash alongside ongoing net losses and cash burn.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.
OpenAI
Proceed
Claude
Caution
Gemini
Proceed